Promomed registered the first fully Russian tirzepatide

Promomed has registered a drug for reducing excess weight and treating obesity, Tirzetta. It is the first Russian competitor of the well-known and not available in Russia drug Mounjaro. According to Strategy Partners' research, the Russian market for drugs to combat overweight and diabetes will grow by almost 80% to reach ₽17 billion in 2025.